Application of Gypensapogenin B in medicament for treating osteoporosis caused by anti-estrogenic deficiency

An anti-estrogen deficiency and osteoporosis technology, applied in drug combinations, medical preparations containing active ingredients, bone diseases, etc., can solve problems such as increased thrombus, osteonecrosis of the jaw, and uncertain long-term curative effect

Inactive Publication Date: 2013-02-13
JIANGSU KANGHENG CHEM
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although bisphosphonates are effective, they can cause serious adverse reactions such as osteonecrosis of the jaw, musculoskeletal pain, and renal failure; although hormone replacement therapy is an important method to prevent and treat postmenopausal osteoporosis, long-term us

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin B in medicament for treating osteoporosis caused by anti-estrogenic deficiency
  • Application of Gypensapogenin B in medicament for treating osteoporosis caused by anti-estrogenic deficiency
  • Application of Gypensapogenin B in medicament for treating osteoporosis caused by anti-estrogenic deficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1: Preparation of Gypensapogenin B tablets of the compound involved in the present invention:

[0015] Take 20 grams of compound Gypensapogenin B, add 180 grams of conventional excipients for preparing tablets, mix them, and prepare 1,000 tablets with a conventional tablet press.

Embodiment 2

[0016] Example 2: Preparation of the compound Gypensapogenin B capsule of the present invention:

[0017] Take 20 grams of the compound Gypensapogenin B, add 180 grams of conventional auxiliary materials for preparing capsules, such as 180 grams of starch, mix well, and encapsulate to make 1000 tablets.

[0018] The following pharmacodynamic experiments will further illustrate its drug activity.

[0019] 1. Materials and methods

[0020] Ten-week-old healthy female SD rats (18, Jiangsu Animal Center) were randomly divided into 3 groups, each with 6 rats: sham operation group (Sham), ovariectomized model group (OVX), and Gypensapogenin B group. Feeding conditions: temperature is (23 ± 2) ℃, light: dark is 12:12. Let the rats in each group adapt to the environment for 2 weeks before starting the osteoporosis modeling operation: rats in each group were anesthetized by intraperitoneal injection of 20% urethane (6ml / kg body weight), the Sham group was opened and the abdomen was closed, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses novel application of Gypensapogenin B in medicament for treating osteoporosis. Osteoporosis is one of vital diseases which are harmful to human health, and the number of patients with osteoporosis is increased progressively along with aging of population, which brings huge social, medical and economical burden to the whole world. Although home and abroad related experts and scholars pay attention to prevention and treatment of osteoporosis, an effective treatment medicament to the disease does not exist. In vivo tests discover that the Gypensapogenin B has remarkable effect in resisting osteoporosis. Experiment results indicate that the Gypensapogenin B can inhibit strengthening of bone conversion caused by ovariectomized, so that bone is less destroyed, the blood calcium concentration can be improved, and bone deposition are favored. The Gypensapogenin B has treatment effect on osteoporosis caused by anti-estrogenic deficiency, and does not have estrogen-like side effect.

Description

Technical field [0001] The present invention relates to the field of medicines related to anti-osteoporosis, in particular to a new use of Gypensapogenin B for preventing and treating osteoporosis. Background technique [0002] Osteoporosis is a systemic, metabolic bone disease characterized by reduction and loss of bone mass, bone fragility and increased risk of fractures. With the aging of the population, the incidence of osteoporosis has also increased rapidly. It has become an important disease endangering human health and has brought a huge social and economic burden to the world. Although relevant experts and scholars at home and abroad attach great importance to the prevention and treatment of this disease, there is still a lack of effective treatment drugs for this disease. [0003] Currently commonly used clinical drugs for preventing and treating osteoporosis include estrogen replacement drugs, bisphosphonates, selective estrogen receptor modulators, vitamin D, parathyro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P19/10
Inventor 吴俊艺王泽正吴俊华
Owner JIANGSU KANGHENG CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products